Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.

CompletedOBSERVATIONAL
Enrollment

204

Participants

Timeline

Start Date

July 14, 2016

Primary Completion Date

October 9, 2017

Study Completion Date

July 31, 2018

Conditions
Ovarian Neoplasms
Interventions
PROCEDURE

Pelvic imaging

Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.

PROCEDURE

Blood draw

Within 60 days prior to, or on the day of the pelvic mass surgery, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.

PROCEDURE

laparotomy or laparoscopy

A laparotomy or laparoscopic procedure will be performed by a qualified individual for excision of the pelvic mass. Representative tissue samples will be taken from the excised pelvic mass and evaluated in pathology departments within each institution according to institutional guidelines. Results from the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.

Trial Locations (5)

12157

Vivantes Auguste-Viktoria-Klinikum, Berlin

12351

Vivantes-Klinikum Neukölln, Berlin

13353

Charité - Universitätsmedizin Berlin, Berlin

13509

Vivantes Humboldt-Klinikum, Berlin

A-1090

Medical University of Vienna, Vienna

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Medical University of Vienna

OTHER

collaborator

Charite University, Berlin, Germany

OTHER

collaborator

Vivantes Netzwerk für Gesundheit GmbH

OTHER

lead

Angle plc

INDUSTRY

NCT02785731 - Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass. | Biotech Hunter | Biotech Hunter